A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434

The authors assessed the overall response rate, including confirmed complete response (CR) and partial response, in patients with relapsed/refractory multiple myeloma treated with sorafenib. Qualitative and quantitative toxicities associated with this regimen were evaluated. Patients were eligible i...

Descripción completa

Detalles Bibliográficos
Autores principales: Srkalovic, Gordan, Hussein, Mohamad A, Hoering, Antje, Zonder, Jeffrey A, Popplewell, Leslie L, Trivedi, Harsha, Mazzoni, Sandy, Sexton, Rachel, Orlowski, Robert Z, Barlogie, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302677/
https://www.ncbi.nlm.nih.gov/pubmed/24913924
http://dx.doi.org/10.1002/cam4.276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302677/
https://www.ncbi.nlm.nih.gov/pubmed/24913924
http://dx.doi.org/10.1002/cam4.276

Ejemplares similares